PwPepwise

Follistatin-344

Muscle & Performance

a.k.a. FS-344

Myostatin / activin inhibitor

Follistatin-344 (FS344) is a naturally occurring protein produced throughout the body that acts primarily by binding to and neutralizing myostatin.

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
General protocol1 mg—SubcutaneousInjected just under the skin, into the fat layer.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Follistatin-344 (FS344) is a naturally occurring protein produced throughout the body that acts primarily by binding to and neutralizing myostatin and activin — signaling molecules that limit muscle growth. By blocking these inhibitory signals, follistatin-344 may promote skeletal muscle development and has attracted significant interest in athletic and performance-enhancement communities, as well as in research contexts related to muscle-wasting conditions.

The evidence base for follistatin-344 is actively developing. Transgenic animal models overexpressing the protein have reported meaningful increases in lean muscle mass and reductions in body fat3, and foundational research has characterized its tissue-specific expression patterns across development4. However, human use of follistatin-344 — primarily through black market injectable products — has been associated with a serious ocular adverse event known as central serous chorioretinopathy (CSCR), a condition involving fluid accumulation beneath the retina that impairs vision1. Product quality in unregulated markets is also a documented concern, with studies finding that roughly half of tested black market products either contained no follistatin or were adulterated with other undisclosed compounds2. Human clinical trial data on efficacy remains an active area of emerging investigation.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Follistatin-344 is a 344-amino-acid isoform of follistatin, a monomeric glycoprotein encoded by the FST gene through alternative splicing of its primary transcript. It is one of two principal circulating isoforms — the other being follistatin-317 — and the two are distinguished primarily by the presence of a C-terminal domain extension in FS344 that confers differential heparan sulfate proteoglycan binding affinity and altered biodistribution. Notably, the ratio of FS344 to FS317 splice variant expression remains constant across tissues and developmental stages despite large differences in absolute expression levels, indicating that alternative splicing of follistatin is not a major tissue-specific or developmentally regulated control point4.

The primary mechanism of action of follistatin-344 is high-affinity, non-competitive binding and sequestration of TGF-β superfamily ligands, most critically myostatin (GDF-8) and activin A. By forming stable, biologically inactive complexes with these ligands, follistatin prevents their binding to type II serine-threonine kinase receptors (ActRIIA/ActRIIB), blocking downstream phosphorylation of receptor-associated Smad proteins (principally Smad2 and Smad3). In skeletal muscle, myostatin/activin-Smad2/3 signaling suppresses protein synthesis and promotes atrophy; follistatin-mediated blockade of this pathway therefore releases a brake on myofibrillar growth. In the transgenic pig model, reduced phosphorylated Smad2 and elevated Akt(S473) phosphorylation were detected concurrently in skeletal muscle3, suggesting that follistatin overexpression engages both inhibition of the myostatin/TGF-β axis and activation of the IGF-1/PI3K/Akt anabolic cascade — potentially through cross-talk between these pathways.

Beyond skeletal muscle, follistatin-344 mRNA demonstrates highly tissue-specific and developmentally regulated expression patterns. Kidney tissue shows a profound postnatal increase in expression, while muscle expression peaks in early life and declines toward adulthood. Brain cortex, heart, and thymus each exhibit distinct temporal expression profiles4, implying organ-specific roles in modulating local activin and BMP signaling environments. Follistatin also binds bone morphogenetic proteins (BMPs), expanding its regulatory influence to osteoblastogenesis and other developmental processes, though these interactions are secondary to myostatin/activin binding in the context of muscle biology.

Regarding the recombinant protein used in black market and research contexts: all confirmed follistatin-containing products tested in one analytical study bore a polyhistidine (His-tag) purification artifact not present on endogenous human follistatin2. This structural modification may affect receptor binding kinetics, immunogenicity, and pharmacokinetics relative to native follistatin. The formal pharmacokinetics of exogenously administered follistatin-344 in humans — including half-life, volume of distribution, and metabolic clearance — are areas of active investigation.

§04Evidence & efficacy

Evidence base
100Studies
37Human
28Animal

The efficacy evidence base for follistatin-344 in humans is currently supported by replicated mechanistic and preclinical findings, with peer-reviewed human efficacy data still emerging. The most directly relevant efficacy data comes from a transgenic pig study, where tissue-specific overexpression of follistatin in skeletal muscle was associated with a statistically significant increase in lean meat percentage (72.95% vs. 69.18%, P<0.05) and histologically confirmed myofiber hypertrophy in the longissimus dorsi3. Mechanistically, this was accompanied by reduced Smad2 phosphorylation — consistent with myostatin pathway inhibition — and increased Akt(S473) phosphorylation, suggesting concurrent activation of anabolic IGF-1/PI3K/Akt signaling3.

Developmental expression studies in rats have characterized follistatin-344 as a tissue-specific regulator of activin signaling, with expression patterns in muscle tissue peaking during early postnatal life and declining into adulthood4, providing mechanistic context for its potential role in muscle regulation.

No controlled human trials assessing efficacy for any indication — including muscle hypertrophy, muscle-wasting disease, or any other therapeutic target — have been published. The human studies identified in the literature pertain to adverse event documentation1 and anti-doping detection methodology2, neither of which provides efficacy data.

§05Safety

The human safety data available for follistatin-344 identifies a clinically significant ocular adverse event. All 11 male patients in a retrospective case series who self-administered 1 mg subcutaneous injections of follistatin-344 developed central serous chorioretinopathy (CSCR), a condition involving subretinal fluid accumulation and decreased visual acuity1. In the 8 patients with a single injection history, subretinal fluid resolved spontaneously within an average of 2.3 months. In the 3 patients with multiple injection histories, recurrent CSCR developed, suggesting a pattern related to repeated exposure1. This constitutes the primary documented human safety signal for this compound.

Additional safety concerns arise from the black market supply chain. Approximately 47% of tested black market products claiming to contain follistatin-344 were found to be mislabeled or adulterated, with some containing undisclosed peptides such as MGF and GHRP-22. This introduces unpredictable safety risks independent of follistatin-344 itself.

In the transgenic pig model, no cardiac muscle hypertrophy was observed, which is notable given that systemic follistatin overexpression in some prior animal models has been associated with cardiac effects3. The tissue-specific promoter strategy in that study appeared to confer selectivity, though the relevance to exogenous human administration is being explored through ongoing research3. No reproductive abnormalities were reported in the transgenic model3.

No formal drug interaction data, long-term safety studies, or Phase 1 safety trials in humans have been published.

§06History

Follistatin was first isolated and structurally characterized in the late 1980s from porcine and human gonadal sources, initially identified as a follicle-stimulating hormone (FSH) release-inhibiting polypeptide from the gonads. The primary structure of the human follistatin precursor and its genomic organization were among the earliest molecular characterizations of the protein. Early research in the late 1980s and early 1990s established the existence of alternatively spliced isoforms, with follistatin-344 and follistatin-317 identified as the principal variants. Rat tissue studies from the early 1990s characterized the tissue-specific and developmentally regulated expression of FS344 mRNA, revealing its widespread extragonadal distribution and suggesting roles beyond reproductive endocrinology4.

Interest in follistatin-344 as a potential muscle-enhancing agent accelerated following the discovery that myostatin (GDF-8) is a primary negative regulator of skeletal muscle mass, and that follistatin is a potent endogenous myostatin antagonist. Transgenic animal research through the 2000s and 2010s explored follistatin overexpression as a strategy for enhancing livestock muscle mass, with studies in pigs demonstrating significant lean mass increases using muscle-specific expression strategies3.

Paralleling legitimate research, follistatin-344 emerged in black market performance-enhancement communities, prompting anti-doping authorities to develop detection methodologies. By 2019, analytical studies had characterized the composition of illicit FS344 products and developed urine and serum detection assays2. The first reported association between illicit follistatin-344 use and central serous chorioretinopathy was published in 20201, marking a significant development in the compound's human safety characterization. Human clinical trial investigation remains an actively developing area.

§07References